Preclinical research into cognition enhancers

Trends in Pharmacological Sciences

Volumn 27, Issue 11, 2006, Pages 602-608

  Sarter, Martin ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; A 412997; ACETYLCHOLINE; AMPA RECEPTOR AGONIST; ATOMOXETINE; CX 717; DIHYDREXIDINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 4 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; GLYCINE TRANSPORTER 1 ANTAGONIST; KT 90; MEM 1414; MU OPIATE RECEPTOR AGONIST; MUSCARINIC AGENT; N (4 ACETYL 1 PIPERAZINYL) 4 FLUOROBENZAMIDE; NEUROTRANSMITTER; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; RECEPTOR BLOCKING AGENT; RIMONABANT; RO 046790; SEROTONIN 4 AGONIST; SEROTONIN 6 ANTAGONIST; SEROTONIN ANTAGONIST; SL 650155; SSR 504734; UNCLASSIFIED DRUG; XANOMALINE;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; COGNITIVE DEFECT; CONSTRUCT VALIDITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESEARCH; FACE VALIDITY; FALSE POSITIVE RESULT; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIGH THROUGHPUT SCREENING; MAZE TEST; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SCHIZOPHRENIA; TREATMENT RESPONSE;

ANIMALS; BEHAVIOR, ANIMAL; COGNITION; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, ANIMAL; NEURONS; NOOTROPIC AGENTS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 33750015291     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.09.004     Document Type: Review

References (44)

1. Buchanan R.W., et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 31 (2005) 5-19
2. Hagan J.J., and Jones D.N. Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr. Bull. 31 (2005) 830-853
3. Floresco S.B., et al. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr. Bull. 31 (2005) 888-894
4. Sarter M. Taking stock of cognition enhancers. Trends Pharmacol. Sci. 12 (1991) 456-461
5. Sarter M., et al. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: part I. Psychopharmacology (Berl.) 107 (1992) 144-159
6. Sarter M., et al. Behavioral screening for cognition enhancers: from indiscriminate to valid testing: part II. Psychopharmacology (Berl.) 107 (1992) 461-473
7. Hiramatsu M., et al. Pharmacological characterization of the ameliorating effect on short-term memory impairment and antinociceptive effect of KT-90 in mice. Behav. Brain Res. 160 (2005) 374-381
8. 6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology 30 (2005) 2169-2179
9. Sarter M., and Bruno J.P. Animal models in biological psychiatry. In: D'haenen H., et al. (Ed). Textbook of Biological Psychiatry (2002), John Wiley & Sons 37-44
10. Decker M.W. Animal models of cognitive function. Crit. Rev. Neurobiol. 9 (1995) 321-343
11. Sarter M. Animal cognition: defining the issues. Neurosci. Biobehav. Rev. 28 (2004) 645-650
12. Sarter M., and Sunderland R.J. Neurobiology of cognition in laboratory animals: challenges and opportunities. Neurosci. Biobehav. Rev. 28 (2004) 643
13. Sullivan J.P., et al. ABT-089 [2-methyl-3-(2-S-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J. Pharmacol. Exp. Ther. 283 (1997) 235-246
14. Levin E.D., et al. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl.) 184 (2006) 523-539
15. Wilens T.E., et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol. Psychiatry 59 (2006) 1065-1070
16. Arneric S.P., et al. S-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization. J. Pharmacol. Exp. Ther. 270 (1994) 310-318
17. Buccafusco J.J., et al. Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement. Psychopharmacology (Berl.) 120 (1995) 256-266
18. McGaughy J., et al. Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. Psychopharmacology (Berl.) 144 (1999) 175-182
19. Wilens T.E., et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 156 (1999) 1931-1937
20. Potter A., et al. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. Psychopharmacology (Berl.) 142 (1999) 334-342
21. Jones G.M., et al. Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology (Berl.) 108 (1992) 485-494
22. Decker M.W., et al. S-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J. Pharmacol. Exp. Ther. 270 (1994) 319-328
23. Rueter L.E., et al. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders. CNS Drug Rev. 10 (2004) 167-182
24. Mansvelder H.D., et al. Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacology (Berl.) 184 (2006) 292-305
25. Prendergast M.A., et al. Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology (Berl.) 136 (1998) 50-58
26. Young J.W., et al. Nicotine improves sustained attention in mice: evidence for involvement of the α7 nicotinic acetylcholine receptor. Neuropsychopharmacology 29 (2004) 891-900
27. Hahn B., et al. Attentional effects of nicotinic agonists in rats. Neuropharmacology 44 (2003) 1054-1067
28. Woodruff-Pak D.S., et al. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2089-2094
29. Granon S., et al. Nicotinic and muscarinic receptors in the rat prefrontal cortex: differential roles in working memory, response selection and effortful processing. Psychopharmacology (Berl.) 119 (1995) 139-144
30. Man, K. et al. Nicotine- and ABT-089-evoked cholinergic signals in the cortex: neuropharmacological mechanisms and functions. Soc. Neurosci. Abs. 31, 163.7
31. Robbins T.W. Homology in behavioural pharmacology: an approach to animal models of human cognition. Behav. Pharmacol. 9 (1998) 509-519
32. Willner P. Methods for assessing the validity of animal models of human psychopathology. In: Boulton A.A., et al. (Ed). Animal models in Psychiatry (1991), Humana Press 1-23
33. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 160 (2003) 13-23
34. Martinez V., et al. Sensitized attentional performance and Fos-immunoreactive cholinergic neurons in the basal forebrain of amphetamine-pretreated rats. Biol. Psychiatry 57 (2005) 1138-1146
35. Bentley P., et al. Effects of cholinergic enhancement on visual stimulation, spatial attention, and spatial working memory. Neuron 41 (2004) 969-982
36. Mattay V.S., et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6186-6191
37. Sutherland R.J., and Hamilton D.A. Rodent spatial navigation: at the crossroads of cognition and movement. Neurosci. Biobehav. Rev. 28 (2004) 687-697
38. Lavie N. Distracted and confused? Selective attention under load. Trends Cogn. Sci. 9 (2005) 75-82
39. Robbins T.W. Chemistry of the mind: neurochemical modulation of prefrontal cortical function. J. Comp. Neurol. 493 (2005) 140-146
40. Moser P.C., et al. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J. Pharmacol. Exp. Ther. 302 (2002) 731-741
41. Nordholm A.F., et al. Linopirdine does not improve matching performance in the titrating matching-to-sample paradigm. Pharmacol. Biochem. Behav. 52 (1995) 205-210
42. Sarter M.F., and Bruno J.P. Cognitive functions of cortical ACh: lessons from studies on trans-synaptic modulation of activated efflux. Trends Neurosci. 17 (1994) 217-221
43. Kozak R., et al. Augmented prefrontal acetylcholine release during challenged attentional performance. Cereb. Cortex 16 (2006) 9-17
44. Sarter M., et al. Cortical cholinergic transmission and cortical information processing following psychostimulant-sensitization: implications for models of schizophrenia. Schizophr. Bull. 31 (2005) 117-138